ReviewCardiology research and practice2026
Nutraceuticals for Preventing and Managing Cancer Chemotherapy-Induced Cardiotoxicity: An Updated Comprehensive Review.
Review in Cardiology research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nutraceuticals for Preventing and Managing Cancer Chemotherapy-Induced Cardiotoxicity: An Updated Comprehensive Review.Cardiology research and practice · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemotherapy-induced cardiotoxicity remains a major barrier to durable cancer control and survivor well-being, arising from oxidative stress, mitochondrial injury, inflammation, and emerging pyroptotic pathways. This updated narrative review integrates mechanistic and clinical data on nutraceuticals, including amino acids, fatty acids, vitamins, minerals, and polyphenols. Consistent clinical signals include omega-3 fatty acids, alpha-lipoic acid, vitamin D, coenzyme Q10, black seed oil, and vitamin E with levocarnitine, which primarily reduce oxidative stress to protect against cardiotoxicity. Additional preclinical and early clinical work highlights vitamin C-, taurine-, zingerone-, and rosemary-derived phenolics as candidates that target oxidative and inflammatory injury without compromising antitumor activity. Translation to care should be prevention-focused, pairing baseline risk assessment with surveillance that utilizes high-sensitivity troponin, natriuretic peptides, and advanced echocardiography, such as global longitudinal strain. Nutraceuticals should complement rather than replace established oncologic therapy and cardioprotection, with integration guided by individual risk and ongoing monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.